Actimid

Actimid™

An immunomodulatory molecular analogue of thalidomide, which has shown promise in phase 2 studies for managing myeloma, and possibly other cancers.
Adverse effects BM suppression with anaemia, thrombocytopaenia, neutropaenia, diarrhoea, fever, muscle cramps, neuropathy, constipation, rash, fatigue.
References in periodicals archive ?
In addition to analysis of the overall world market, our study shows you revenue forecasting of five products to 2022: -- Revlimid -- Thalomid -- Actimid -- Velcade -- Kyprolis.
James Evans, a pharmaceutical industry analyst in visiongain, said: “The years 2012 to 2013 will see two important new products reach the market, Onyx's Kyprolis and Celgene's Actimid.
The pharmaceutical industry analyst in visiongain, said: "The years 2012 to 2013 will see two important new products reach the market, Onyx's Kyprolis and Celgene's Actimid.
Table 26: Ongoing Phase II trial for Actimid in MM, 2007 64
Avodart, Zoladex, Proscar, Casodex, Taxotere, Satraplatin, Plenaxis, EULEXIN, Trelstar Depot, Trelstar LA, Viadur, Gleevec, Avastin, Herceptin, Atrasentan, Acapodene, Actimid, OSI-461, Revimid, Eladem, GTI-2501, ILX-651, calcitrol, Genasense, Provenge , GVAX, SGN-15, Thalomid, Velcade, Lupron Depot, Histrelin, Eligard, ILX651, Vitaxin, J591, CG7870, BBR-3576, PCK3145, Leuvectin, Leuprolide, ProMaxx-100, Osaterone, Prinomastat, BLP25, Metaret, Chimax, Drogenil, Flutamide, EULEXIN, Onconase, IM862, MDX-010, Erbitux, Eladem, GTI-2040, Apomine, Eflornithine, Doxil, GTI-2501, Thalidomide, TG4010, KRX-0401, Yondelis, TRICOM Vaccine, Zarnestra
These R&D expenditures continue to support ongoing clinical progress in multiple proprietary development programs for THALOMID, REVLIMID, ACTIMID, for other immunomodulatory drugs such as CC-11006 and CC-10050, as well as in the PDE4/TNF alpha, kinase and ligase inhibitor programs and stem cell program.
REVLIMID and ACTIMID are members of a new class of novel immunomodulatory drugs, or IMiDs which may demonstrate, in clinical studies, anticancer response.
Clinical investigators from prominent cancer research centers will report data from recent and on-going clinical trials of THALOMID, REVLIMID, ACTIMID and ALKERAN in a broad range of cancers at both the Annual Meeting of the American Society of Hematology (ASH), the largest hematology meeting in the world, in San Diego, CA from December 3-7, 2004 and Chemotherapy Foundation Symposium in New York City from November 10-12.
Forty-one Abstracts on THALOMID, REVLIMID, ACTIMID and ALKERAN as Single Agents and in Combination Therapies
These R&D expenditures are supporting ongoing rapid clinical progress in multiple core development programs in THALOMID, REVIMID, ACTIMID and in Celgene's lead Class II IMiD(TM) CC-11006, as well as in its high potential SelCID(TM) and kinase inhibitor programs.
Celgene Corporation announced today that data evaluating clinical results on ACTIMID (CC-4047) as a therapeutic approach for patients with relapsed/refractory multiple myeloma was presented at the American Association of Hematology 45th Annual Meeting in San Diego, one of the world's largest oncology meetings.
Celgene Corporation announced today that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials of ACTIMID in multiple myeloma and its mechanism of action at the American Society of Hematology 45th Annual Meeting, one of the largest oncology meetings in the world, in San Diego, CA from December 5-9, 2003.